Parkinson's Disease (PD) currently lacks effective treatments to slow its progression, causing significant health and financial challenges for patients and their families. Fastprinciple’s therapeutic solution for Parkinson's Disease (PD) aims to slow disease progression. By slowing down the progression of PD, Fastprinciple’s solution promises significant benefits for patients and their caregivers, enhancing quality of life and reducing economic burdens. The company also plans to apply this approach to other neurological disorders, expanding its impact and commercial opportunities. Fastprinciple is dedicated to advancing this innovative treatment and collaborating with key partners to bring it to market successfully.
Economically, the solution could yield a benefit of $75,891 per patient, disrupting the PD treatment market and enhancing the EU’s economic competitiveness, especially with an estimated 17 million PD patients by 2040. Environmentally, Fastprinciple is committed to ensure sustainable. Job creation our the project future plans includes hiring additional R&D staff and other key personnel. Aligning with UN Sustainable Development Goals, the solution aims to ensure healthy lives (Goal 3), support economic growth and employment (Goal 8), and foster innovation (Goal 9) by developing new molecules for other neurological disorders.
The current grant, aimed to support Fastprinciple extending its patent protection to several countriesand to developed an exploitation plan through discussions with key players in the pharmaceutical industry, investors, and advisors. These discussions, facilitated by direct contacts and participation in international conferences, were vital for refining Fastprinciple’s R&D strategy, aligning financial requirements, adjusting business plans, and identifying potential investors and customers. This collaborative approach aims to support the next stages of Fastprinciple’s pipeline and business development, moving towards clinical trials and financial sustainability.
